AI Article Synopsis
- Researchers have been focusing on the levels of choline and ethanolamine plasmalogens (PC-Pls and PE-Pls) in human plasma, as reduced levels are seen in patients with neurodegenerative disorders.
- Accurate quantification using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is challenging due to issues like low ion production from PC-Pls and extraction complications.
- A new optimized LC-MS/MS method was developed that allows for precise detection and quantification of plasmalogens at very low concentrations, aiding in the analysis of these compounds in both healthy individuals and Alzheimer's patients.
Article Abstract
Concentration of both choline plasmalogen (PC-Pls) and ethanolamine Pls (PE-Pls) in human plasma/serum has been getting attention to, since certain patients including those with neurodegenerative disorders, have been reported to exhibit reduced levels of specific Pls species. However, despite using liquid chromatography-tandem mass spectrometry (LC-MS/MS), accurate quantitation of Pls is still difficult because of less product ion from PC-Pls and quantitative issues (e.g., extraction recoveries and matrix effects). The present study aimed to develop a method for accurate identification and quantitation of Pls molecular species using LC-MS/MS operated in the multiple reaction monitoring mode. The LC-MS/MS conditions in the presence of sodium, and the extraction method using methanol protein precipitation were optimized. Under the optimal condition, Pls was detected at femtomole levels. The recoveries of Pls from human plasma were nearly 100%, and matrix effects were not observed. The novel method enabled determination of each Pls species in human plasma at the concentrations of 0.5-13.6μM. Then the PC-Pls and PE-Pls species in the plasma of both healthy subjects and patients with Alzheimer's disease were quantitated. The method developed herein represents a powerful tool for analyzing Pls, which may provide a better understanding of their physiological roles in vivo.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpba.2016.11.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A lever hypothesis for Synaptotagmin-1 action in neurotransmitter release.
Proc Natl Acad Sci U S A
January 2025
Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390.
Neurotransmitter release is triggered in microseconds by Ca-binding to the Synaptotagmin-1 C-domains and by SNARE complexes that form four-helix bundles between synaptic vesicles and plasma membranes, but the coupling mechanism between Ca-sensing and membrane fusion is unknown. Release requires extension of SNARE helices into juxtamembrane linkers that precede transmembrane regions (linker zippering) and binding of the Synaptotagmin-1 CB domain to SNARE complexes through a "primary interface" comprising two regions (I and II). The Synaptotagmin-1 Ca-binding loops were believed to accelerate membrane fusion by inducing membrane curvature, perturbing lipid bilayers, or helping bridge the membranes, but SNARE complex binding through the primary interface orients the Ca-binding loops away from the fusion site, hindering these putative activities.
View Article and Find Full Text PDFExploring associations between the FTO rs9939609 genotype and plasma concentrations of appetite-related hormones in adults with obesity.
PLoS One
January 2025
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Associations between variants in the FTO locus and plasma concentrations of appetite related hormones are inconsistent, and might not work in a dose dependent fashion in people with obesity. Moreover, it is relevant to report meal related plasma concentrations of these hormones in persons with obesity given the growing interest in their pharmacological potential in obesity therapy. We find it clinically relevant to examine associations between the SNP rs9939609 genotypes and homeostatic appetite regulation in individuals with BMI ≥35 kg/m2.
View Article and Find Full Text PDFPlasma neutrophil gelatinase-associated lipocalin as a single test rule out biomarker for acute kidney injury: A cross-sectional study in patients admitted to the emergency department.
PLoS One
January 2025
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Objectives: Acute kidney injury (AKI) is a syndrome with high mortality and morbidity in part due to delayed recognition based on changes in creatinine. A marker for AKI based on a single measurement is needed and therefore the performance of a single measurement of plasma neutrophil gelatinase-associated lipocalin (pNGAL) to predict AKI in patients admitted to the emergency department was tested.
Methods: Samples from the Triage study which included 6005 consecutive adult patients admitted to the emergency department were tested for pNGAL.
Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis.
Medicine (Baltimore)
January 2025
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background: This study evaluates the efficacy and safety of sitagliptin versus gliclazide, combined with metformin, in treatment-naive patients with type 2 diabetes mellitus (T2DM) and glucotoxicity.
Methods: In this single-center, randomized, controlled noninferiority trial, 129 treatment-naive patients with T2DM with glucotoxicity (fasting plasma glucose [FPG] ≥ 200 mg/dL and glycated hemoglobin ≥ 9.0%) were randomized to receive sitagliptin plus metformin (n = 66) or gliclazide plus metformin (n = 63) for 12 weeks.
Ultrasensitive detection of intact SARS-CoV-2 particles in complex biofluids using microfluidic affinity capture.
Sci Adv
January 2025
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Measuring virus in biofluids is complicated by confounding biomolecules coisolated with viral nucleic acids. To address this, we developed an affinity-based microfluidic device for specific capture of intact severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach used an engineered angiotensin-converting enzyme 2 to capture intact virus from plasma and other complex biofluids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!